Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

The primary purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of GTAEXS617 (REC-617) in participants with advanced solid tumors.

Trial Details

NCT ID
NCT05985655
Phase
PHASE1 / PHASE2
Sponsor
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • GTAEXS617
  • SoC
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Grand Rapids, Michigan, United States|42.96336,-85.66809
  • New York, New York, United States|40.71427,-74.00597
  • Columbus, Ohio, United States|39.96118,-82.99879
  • San Antonio, Texas, United States|29.42412,-98.49363

Key Eligibility Criteria

  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
  • Life expectancy \> 3 months.
  • One of the following histologically or cytologically confirmed advanced solid tumors: head and neck squamous cell carcinoma (HNSCC), pancreatic ade…
  • Must have disease that is advanced (ie, surgery or radiotherapy are not considered to be potentially curative), recurrent, or metastatic following …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →